^
ALK positive
NSCLC
alectinib
Sensitive: A1 - Approval
Future Oncol - 2 days - (New C3)
FAT1 mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
NPJ Precis Oncol - 2 days - (New C3)
Chr del(9)(p21.3)
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Resistant: C3 – Early Trials
NPJ Precis Oncol - 2 days - (New C3)
MET amplification + MET exon 14 mutation + EGFR exon 20 insertion
LUAD
crizotinib
Sensitive: C4 – Case Studies
BMC Med Genomics - 2 days - (New C4)
NF2 deletion
Malignant Pleural Mesothelioma
IK-930
Sensitive: B - Late Trials
Ikena Oncology Press Release - 3 days - (New B)
MET exon 14 mutation
NSCLC
capmatinib
Sensitive: A1 - Approval
Novartis Press Release - 3 days - (New A1)
EGFR exon 20 insertion
NSCLC
osimertinib
Sensitive: C2 – Inclusion Criteria
Lung Cancer - 3 days - (New C3)
TMB-H
NSCLC
Immunotherapy
Sensitive: B - Late Trials
Lung Cancer - 5 days - (New C3)
EGFR mutation
NSCLC
pemetrexed
Sensitive: C2 – Inclusion Criteria
Int J Clin Oncol - 5 days - (New C3)
PD-L1 overexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Lung Cancer - 5 days - (New C3)
STK11 mutation
NSCLC
Immunotherapy
Resistant: C3 – Early Trials
Lung Cancer - 5 days - (New C3)
KEAP1 mutation
NSCLC
Immunotherapy
Resistant: C3 – Early Trials
Lung Cancer - 5 days - (New C3)
STK11 mutation + KEAP1 mutation + KRAS G12C
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Lung Cancer - 5 days - (New C3)
KDR expression
NSCLC
Immunotherapy
Resistant: C3 – Early Trials
Cancer Sci - 5 days - (New C3)
EGFR mutation
NSCLC
osimertinib
Sensitive: A2 - Guideline
Future Oncol - 1 week - (New C3)
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive: A1 - Approval
BMC Cancer - 1 week - (New C3)
EGFR L858R
NSCLC
osimertinib
Sensitive: A1 - Approval
Onco Targets Ther - 1 week - (New C4)
EGFR mutation
NSCLC
dacomitinib
Sensitive: A1 - Approval
Front Pharmacol - 1 week - (New C3)
EGFR L858R
NSCLC
erlotinib
Sensitive: A1 - Approval
Onco Targets Ther - 1 week - (New C4)
EGFR exon 19 deletion + PD-L1 expression
NSCLC
osimertinib
Sensitive: C3 – Early Trials
Sci Rep - 1 week - (New C3)
FOXM1 rs3742076_G
NSCLC
gefitinib
Resistant: C3 – Early Trials
Clin Cancer Res - 1 week - (New C3)
EML4-ALK variant 2
LUAD
ALK inhibitor
Sensitive: C4 – Case Studies
Springer - 1 week - (New C4)
CFTR expression
LUAD
CFTR potentiator
Sensitive: D – Preclinical
J Cancer Res Clin Oncol - 1 week - (New D)
No biomarker
NSCLC
sugemalimab
Sensitive: A1 - Approval
CStone Pharma Press Release - 2 weeks - (New A1)
EGFR exon 19 deletion
NSCLC
EGFR inhibitor
Sensitive: B - Late Trials
Cancer Med - 2 weeks - (New C3)
ROS1 positive
NSCLC
TPX-0005
Sensitive: B - Late Trials
Zai Lab Press Release - 2 weeks - (New C3)
EGFR exon 19 deletion
NSCLC
afatinib
Sensitive: A1 - Approval
Thorac Cancer - 2 weeks - (New C3)
EGFR L858R
NSCLC
afatinib
Sensitive: A1 - Approval
Thorac Cancer - 2 weeks - (New C3)
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive: A1 - Approval
Roche Press Release - 2 weeks - (New A1)
MET exon 14 mutation
NSCLC
crizotinib
Sensitive: A2 - Guideline
Oncology - 2 weeks - (New C3)
EGFR T790M
NSCLC
afatinib
Sensitive: B - Late Trials
Thorac Cancer - 2 weeks - (New C3)
KRAS G12C
NSCLC
MRTX849
Sensitive: B - Late Trials
Cancer Discov - 2 weeks - (New C3)
KDM5C mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks - (New C3)
EGFR L861Q
LUAD
afatinib
Sensitive: C3 – Early Trials
Clin Transl Oncol - 2 weeks - (New D)
PD-L1 overexpression
NSCLC
PD1 inhibitor
Sensitive: C3 – Early Trials
Pharmacoepidemiol Drug Saf - 2 weeks - (New C3)
KMT2C mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks - (New C3)
PD-L1 overexpression
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
Pharmacoepidemiol Drug Saf - 2 weeks - (New C3)
KRAS mutation
NSCLC
durvalumab
Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
MET exon 14 mutation
NSCLC
durvalumab
Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
EGFR exon 19 deletion
NSCLC
durvalumab
Sensitive: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
KMT2C mutation + BCOR mutation + KDM5C mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks - (New C3)
BCOR mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks - (New C3)
PD-L1 overexpression
NSCLC
pembrolizumab + SNK01
Sensitive: C3 – Early Trials
Thorac Cancer - 2 weeks - (New C3)
NTRK2 fusion
NSCLC
durvalumab
Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
EML4-ALK fusion
NSCLC
durvalumab
Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
HER-2 exon 20 insertion
NSCLC
durvalumab
Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
EGFR exon 20 insertion
NSCLC
durvalumab
Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
EGFR L858R
NSCLC
durvalumab
Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
KMT2C mutation + BCOR mutation + KDM5C mutation + TMB-H
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks - (New C3)
KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks - (New C3)
EGFR L861Q
LUAD
osimertinib
Sensitive: C4 – Case Studies
Clin Transl Oncol - 2 weeks - (New D)
FGFR2-ERC1 fusion
LUAD
anlotinib
Sensitive: C4 – Case Studies
Onco Targets Ther - 2 weeks - (New C4)
EGFR exon 19 deletion + EGFR L861Q
LUAD
erlotinib
Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
EGFR L861Q
LUAD
erlotinib
Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
EGFR exon 19 deletion + EGFR L861Q
LUAD
afatinib
Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
EGFR exon 19 deletion + EGFR L861Q
LUAD
osimertinib
Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
EGFR exon 19 deletion + EGFR L861Q
LUAD
dacomitinib
Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
EGFR exon 19 deletion + EGFR L861Q
LUAD
icotinib
Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
EGFR exon 19 deletion + EGFR L861Q
LUAD
gefitinib
Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
EGFR L861Q
LUAD
gefitinib
Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
EGFR L861Q
LUAD
icotinib
Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
EGFR L861Q
LUAD
dacomitinib
Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
EGFR T790M
NSCLC
osimertinib
Sensitive: A1 - Approval
BMC Cancer - 3 weeks - (New C3)
HER-2 mutation
NSCLC
afatinib
Resistant: A2 - Guideline
Target Oncol - 3 weeks - (New C4)
EGFR L858R
NSCLC
furmonertinib
Sensitive: B - Late Trials
Lancet Respir Med - 3 weeks - (New B)
EGFR exon 19 deletion
NSCLC
furmonertinib
Sensitive: B - Late Trials
Lancet Respir Med - 3 weeks - (New B)
NTRK2 fusion
Lung Cancer
larotrectinib
Sensitive: C1 - Off-label
J Clin Oncol - 3 weeks - (New C3)
NTRK1 fusion
Lung Cancer
larotrectinib
Sensitive: C1 - Off-label
J Clin Oncol - 3 weeks - (New C3)
NTRK3 fusion
Lung Cancer
larotrectinib
Sensitive: C1 - Off-label
J Clin Oncol - 3 weeks - (New C3)
EGFR T790M
Lung Cancer
osimertinib
Sensitive: C1 - Off-label
Transl Oncol - 3 weeks - (New D)
EGFR exon 19 deletion
NSCLC
bevacizumab
Sensitive: C2 – Inclusion Criteria
Cancer Manag Res - 3 weeks - (New C3)
MET negative + EGFR mutation
NSCLC
osimertinib + selumetinib
Sensitive: C3 – Early Trials
Clin Cancer Res - 3 weeks - (New C3)
ABCB6 expression
NSCLC
gemcitabine
Resistant: C3 – Early Trials
Cell Mol Life Sci - 3 weeks - (New C3)
CD74-ROS1 fusion
Malignant Pleural Mesothelioma
crizotinib
Sensitive: C4 – Case Studies
J Cancer Res Clin Oncol - 3 weeks - (New C4)
EGFR exon 19 deletion + EGFR G724S
Lung Cancer
dacomitinib
Sensitive: C4 – Case Studies
Invest New Drugs - 3 weeks - (New C4)
PD-L1 expression
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
ramucirumab
Sensitive: A1 - Approval
ALK positive
NSCLC
lorlatinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
gefitinib
Sensitive: A1 - Approval
No biomarker
NSCLC
durvalumab
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ALK fusion
NSCLC
brigatinib
Sensitive: A1 - Approval
KRAS G12C
NSCLC
sotorasib
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
ALK positive
NSCLC
brigatinib
Sensitive: A1 - Approval
ROS1 fusion
NSCLC
entrectinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
tepotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
bevacizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
dacomitinib
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
EGFR T790M
NSCLC
lazertinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
dacomitinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
cemiplimab
Sensitive: A1 - Approval
RET fusion
NSCLC
pralsetinib
Sensitive: A1 - Approval
No biomarker
NSCLC
cisplatin + pemetrexed
Sensitive: A1 - Approval
EGFR mutation
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
gefitinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
ALK positive
NSCLC
crizotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
crizotinib
Sensitive: A1 - Approval
RET fusion
NSCLC
selpercatinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
mobocertinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
durvalumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
erlotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
tislelizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
DP
Sensitive: A1 - Approval
ALK positive
NSCLC
ensartinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
savolitinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
erlotinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
EGFR mutation
NSCLC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
topotecan
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
cisplatin + pemetrexed
Sensitive: A1 - Approval
No biomarker
NSCLC
pemetrexed
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
No biomarker
NSCLC
carboplatin + albumin-bound paclitaxel
Sensitive: A1 - Approval
No biomarker
LUAD
nintedanib
Sensitive: A1 - Approval
EGFR expression
Lung Non-Small Cell Squamous Cancer
necitumumab
Sensitive: A1 - Approval
ALK positive
NSCLC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
BRAF V600E
NSCLC
trametinib + dabrafenib
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
pemetrexed
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
lurbinectedin
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
amivantamab-vmjw
Sensitive: A1 - Approval
No biomarker
NSCLC
docetaxel
Sensitive: A1 - Approval
No biomarker
NSCLC
erlotinib
Sensitive: A1 - Approval
ALK positive
NSCLC
ceritinib
Sensitive: A1 - Approval
No biomarker
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR T790M
NSCLC
aumolertinib
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + erlotinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
erlotinib + ramucirumab
Sensitive: A1 - Approval
No biomarker
NSCLC
erlotinib + Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
NSCLC
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
ALK mutation
NSCLC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
erlotinib + ramucirumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
entrectinib
Sensitive: A1 - Approval
BRAF V600
NSCLC
trametinib + dabrafenib
Sensitive: A1 - Approval
ALK positive
NSCLC
atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
afatinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
tislelizumab
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
NSCLC
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
NSCLC
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
cemiplimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
sintilimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
EGFR mutation
NSCLC
nivolumab + ipilimumab
Sensitive: A2 - Guideline
EGFR mutation + ALK negative + TMB-H
NSCLC
nivolumab + ipilimumab
Sensitive: A2 - Guideline
ROS1 fusion
NSCLC
crizotinib
Sensitive: A2 - Guideline
BRAF V600E
NSCLC
dabrafenib
Sensitive: A2 - Guideline
ROS1 rearrangement
NSCLC
ceritinib
Sensitive: A2 - Guideline